Rob has spent over 30 years financing, developing, manufacturing, and launching medical device and digital health technologies, alongside executing successful exits. Most recently he was CEO at viO HealthTech before the acquisition by Ultrahuman in the summer of 2025. Ultrahuman has a range of health and wellness devices, and the acquisition enabled the launch of a new joint product on the day of the acquisition: Cycle and Ovulation Pro, incorporates algorithms originally developed for viO's OvuSense product developed over 15 years and trained on a dataset of over 260,000 cycles. Now heading up Ultrahuman's Women's Health and Longevity division, Rob continues to help support the inception and growth of startup companies in the medical and digital health fields. His sector experience spans in-vitro diagnostic laboratory and point of care testing; cardiology; obstetrics; gynaecology; fertility; general women’s health; EMG, EEG and sleep neurology; dentistry, and ophthalmology.